You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 11, March 21, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (30)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Pediatrics
 •Pediatrics, Other
 •Leukemias/ Lymphomas
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia

Nobuko Hijiya, MD; Melissa M. Hudson, MD; Shelly Lensing, MS; Margie Zacher, CCRP; Mihaela Onciu, MD; Fred G. Behm, MD; Bassem I. Razzouk, MD; Raul C. Ribeiro, MD; Jeffrey E. Rubnitz, MD, PhD; John T. Sandlund, MD; Gaston K. Rivera, MD; William E. Evans, PharmD; Mary V. Relling, PharmD; Ching-Hon Pui, MD

JAMA. 2007;297:1207-1215.

Context  Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia.

Objectives  To investigate the cumulative incidence of secondary neoplasms in pediatric patients treated for acute lymphoblastic leukemia over 30 years and to characterize late-occurring tumors.

Design, Setting, and Patients  Retrospective study of 2169 patients with acute lymphoblastic leukemia treated between 1962 and 1998 at St Jude Children's Research Hospital, Memphis, Tenn, who achieved complete remission and had a median follow-up time of 18.7 years (range, 2.4-41.3 years).

Main Outcome Measures  Cumulative incidences of secondary neoplasms in first remission and standard incidence ratios of observed rates compared with rates of cancer development in the general US population.

Results  Secondary neoplasms developed as the first event in 123 patients and comprised 46 myeloid malignancies, 3 lymphomas, 14 basal cell carcinomas, 16 other carcinomas, 6 sarcomas, 16 meningiomas, and 22 other brain tumors. The cumulative incidence of secondary neoplasm was 4.17% (SE, 0.46%) at 15 years and increased substantially after 20 years, reaching 10.85% (SE, 1.27%) at 30 years. When meningiomas and basal cell carcinomas were excluded, the overall cumulative incidence was 3.99% (SE, 0.44%) at 15 years and 6.27% (SE, 0.83%) at 30 years, representing a 13.5-fold increase in overall risk compared with the general population. The cumulative incidence of each tumor type at 30 years was 2.19% (SE, 0.32%) for myeloid malignancy, 0.17% (SE, 0.10%) for lymphoma, 3.00% (SE, 0.59%) for brain tumor, 4.91% (SE, 1.04%) for carcinoma, and 0.57% (SE, 0.37%) for sarcoma.

Conclusions  The cumulative incidence of secondary neoplasms increases steadily over 30 years after treatment of acute lymphoblastic leukemia. Although the majority of the late-occurring secondary neoplasms are low-grade tumors, the increase in incidence of more aggressive malignant neoplasms is significantly higher than expected in the general population. These results suggest that lifelong follow-up of acute lymphoblastic leukemia survivors is needed to ascertain the full impact of treatment and other leukemia-related factors on secondary neoplasm development.


Author Affiliations: Departments of Oncology (Drs Hijiya, Hudson, Razzouk, Ribeiro, Rubnitz, Sandlund, Rivera, and Pui), Biostatistics (Ms Lensing), Pharmaceutical Sciences (Drs Evans and Relling), Epidemiology and Cancer Control (Ms Zacher), and Pathology (Drs Onciu and Behm), St Jude Children's Research Hospital, and Departments of Pediatrics and Pharmaceutical Sciences and Pharmacy and the Center for Pediatric Pharmacokinetics and Therapeutics, College of Pharmacy, University of Tennessee Health Science Center (Drs Hijiya, Hudson, Behm, Razzouk, Ribeiro, Rubnitz, Sandlund, Rivera, Evans, Relling, and Pui), Memphis. Dr Behm is now with the Department of Pathology, University of Illinois–Chicago Medical Center, Chicago. Dr Razzouk is now with the Children's Center for Cancer and Blood Diseases, St Vincent Children's Hospital, Indianapolis, Ind.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Acute Lymphoblastic Leukemia
John L. Zeller, Cassio Lynm, and Richard M. Glass
JAMA. 2007;297(11):1278.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treating childhood leukemia without cranial irradiation.
Sallan et al.
NEJM 2009;361:1310-1311.
FULL TEXT  

Late Effects in Long-Term Survivors After Treatment for Childhood Acute Leukemia
Haddy et al.
CLIN PEDIATR 2009;48:601-608.
ABSTRACT  

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui et al.
NEJM 2009;360:2730-2741.
ABSTRACT | FULL TEXT  

Maintenance loses its innocence
Pulsipher
Blood 2009;113:6041-6042.
FULL TEXT  

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
Schmiegelow et al.
Blood 2009;113:6077-6084.
ABSTRACT | FULL TEXT  

High-Risk Populations Identified in Childhood Cancer Survivor Study Investigations: Implications for Risk-Based Surveillance
Hudson et al.
JCO 2009;27:2405-2414.
ABSTRACT | FULL TEXT  

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells
Miller et al.
Blood 2009;113:4289-4299.
ABSTRACT | FULL TEXT  

Cerebral atypical teratoid rhabdoid tumour arising in a child treated for acute lymphoblastic leukaemia
De Padua et al.
BMJ Case Reports 2009;2009:bcr0820080601-bcr0820080601.
ABSTRACT | FULL TEXT  

Typical signature of DNA damage in white blood cells: a pilot study on etheno adducts in Danish mother-newborn child pairs
Arab et al.
Carcinogenesis 2009;30:282-285.
ABSTRACT | FULL TEXT  

Solid cancers after allogeneic hematopoietic cell transplantation
Rizzo et al.
Blood 2009;113:1175-1183.
ABSTRACT | FULL TEXT  

Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990-2004
Pulte et al.
JNCI J Natl Cancer Inst 2008;100:1301-1309.
ABSTRACT | FULL TEXT  

Risk of Subsequent Solid Tumors After Non-Hodgkin's Lymphoma: Effect of Diagnostic Age and Time Since Diagnosis
Hemminki et al.
JCO 2008;26:1850-1857.
ABSTRACT | FULL TEXT  

Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
Barry et al.
JCO 2008;26:1106-1111.
ABSTRACT | FULL TEXT  

Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party
Friedman et al.
Blood 2008;111:939-944.
ABSTRACT | FULL TEXT  

Risk for Second Cancer After Childhood Leukemia
JWatch General 2007;2007:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.